five in Biological Technology

Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes

Harness the Dual Benefits of Freshly Isolated Plateability and the Efficiencies of Cryopreservation CHICAGO, June 16 /PRNewswire/ -- In today's competitive environment and economic climate, the financial implications of being the first to file a promising new drug compound or chemical ...

Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments

PITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as t...

Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics"

A plenary panel discussion on the exciting field of "personal genomics," featuring five of the most outstanding scientists, physicians and commentators in the field, is among the highlights of the 2009 Bio-IT World Conference & Expo being held April 27-29 at the World Trade Center i...

Amgen Positioned to Deliver Attractive Growth Over Next Five Years

NEW YORK, Nov. 7 /PRNewswire-FirstCall/ -- At an Amgen (Nasdaq: AMGN ) meeting of about 200 securities analysts and investors in New York City today, several members of its senior management team outlined the Company's growth strategy, which includes delivering on its pipeline -- including th...

Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting

SOUTH EASTON, Mass., Sept. 23 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" or the "Company") today announced that the Company's pressure cycling technology ("PCT") was highlighted in five separate podium presentations at the Fifth International Conference on Hig...

Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript

BANGKOK, Thailand, Sept. 8 /PRNewswire/ -- Don Margolis, Chairman of The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org ) based in Bangkok, Thailand told The Wall Street Transcript (TWST) in an exclusive news interview published today that future profits inside the stem ...

Desert Radiologists Welcomes Five New Physicians to the Practice

LAS VEGAS, Aug. 26 /PRNewswire/ -- Desert Radiologists, Nevada's largest and most trusted medical imaging company today announced that five new physicians have joined the team of board certified radiologists serving Southern Nevada for over 42 years. (Logo: http://www.newscom.com/cgi-bin/pr...

SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery

LONG BEACH, Calif., Aug. 11 /PRNewswire/ -- It's natural to have concerns before undergoing a surgery, but there are steps you can take beforehand that will make things easier. According to Timothy Schwab, MD, chief medical officer at SCAN Health Plan, planning ahead will help whether you're h...

ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission

FREDERICK, Md., Aug. 6 /PRNewswire/ -- ImQuest BioSciences announced today the successful acquisition of funding from the National Institutes of Health to support the development of a long lasting, safe, and acceptable combination topical microbicide product. ImQuest and a consortium of microb...

First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies

"As one of AFRA's founding members, Europe Aviation is very proud to receive its accreditation," remarks Gregoire Lebigot, Chief Executive Officer of Europe Aviation. "For more than 10 years our vision in the global Valliere Aviation Group (e.g., Europe Aviation, JMV Aviation and B...

Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards

Multiple Cadient Group campaigns honored for creative excellence by communications professionals WEST CONSHOHOCKEN, Pa., June 18 /PRNewswire/ -- Cadient Group, the premier strategic interactive marketing agency serving the healthcare industry, announced today that it has...

Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract

Ferring, Inc. Delivers the Purchase Order Which will Commence the Marketing of Resurgex Select into the Canadian Oncology Market BASKING RIDGE, N.J., March 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (...

AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016

Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen's Efficacy, According to a New Report from Decision Resources WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading...

Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years

Growth will be driven by an increasing physician acceptance of electrophysiology ablation as an effective treatment for atrial fibrillation, according to Millennium Research Group WALTHAM, Mass., March 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets ...

ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting

TORONTO, Feb. 26 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that five abstracts have been selected for presentation at the American Association for Cancer Research (AACR) A...

Dispelling the top five myths about attending networking events

CHICAGONetworking can be a challenge for some people because they either dont understand it or they dont feel the need to participate. People have their own perceptions about the value of networking and when they should network. For some people, networking is only important when a need arises ...

Sonic Foundry gains five university clients for Mediasite

Madison-based Sonic Foundry Inc. has added five universities to the growing number of higher education institutions that use its Mediasite rich media system to power their online distance education. The University of Colorado College of Engineering and Applied Science, Florida State University,...

National Academies induct five UW researchers

Madison, Wis. - Five University of Wisconsin-Madison faculty have won a distinct honor for their research accomplishments: induction into the National Academies . Election to the National Academies - comprised of the National Academy of Sciences , the National Academy of Engineering , the...

A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)

Purpose A previously published application note in this series describes an LC/MS/MS method for the simultaneous determination of four immunosuppressant drugs: Cyclosporin A (CsA), Tacrolimus (TAC, aka FK-506), Sirolimus (SIR, aka Rapamycin) and Everolimus (EVE, aka RAD-001) ...

DOE awards $377 million in funding for 46 energy frontier research centers

...ents a planned DOE commitment of $777 million over five years. EFRC researchers will take advantage of ...zona State University (Tempe, AZ) $14 million for five years to adapt the fundamental principles of natur...niversity of Arizona (Tucson, AZ) $15 million for five years to enhance the conversion of solar energy to...

Novavax Reports Second Quarter 2009 Financial Results

...es recorded at their fair value) as compared to $33.9 million as of December 31, 2008. The company's short-term investments consist of investments in five auction rate securities with a par value of $8.1 million and a fair value of $6.0 million. In addition to the other than temporary impairment discusse...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...ion with Pegasys and ribavirin. After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. There was no evid...

OncoGenex Reports Second Quarter 2009 Financial Results

...aving a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment re...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...itaxel. TAXUS stents have been evaluated by the industry's most extensive randomized, controlled clinical trial program, with patient follow-up out to five years in some cases. BSC's controlled clinical trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval reg...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

...or the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than five million adults worldwide have bipolar disorder. HDAC Inhibitors for Friedreich's Ataxia We are currently developing inhibitors of histone d...

GeoVax Labs, Inc. Provides Clinical Studies Update

...0 Phase 1 trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines. The results of these trials have merited only five phase 2 trials. Progressing to Phase 2 is a significant step for GeoVax. The first injections for the Phase 2a trial were conducted at the HVTN networ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...les of FIRAZYR in Q1 2009 were $0.5 million. With Q2 launches in France and Portugal, FIRAZYR is now launched in nine countries, including four of the five largest European countries. FIRAZYR also received final price publication in Italy during June, which will enable launch in Italy during Q3. FIRAZYR i...

Micromet Closes $80.5 Million Public Offering of Common Stock

...onal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of ...

W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry

...ist Wenying Shou, Ph.D., has been named among the W.M. Keck Foundation's 2009 class of Distinguished Young Scholars in Medical Research. Shou is among five U.S. scientists tapped to receive the five-year, $1 million award, established by Keck to provide resources to promising young scientists in pursuit o...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union, or are medicines which, for economi...ctivate the T cells of a patient's immune system to eliminate cancer cells. five of Micromet's antibodies are currently in clinical trials. Its BiTE antibod...

Cardinal Health Completes Biotech Acquisition

... distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 18 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinalhealth.com . ...

OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results

...aving a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment re...

Bacteria pack their own demise

... can no longer reproduce. Our best-known intestinal residents, Escherichia coli bacteria, more commonly known as E.coli, have such a T-A system in five different locations in their DNA, while Mycobacterium tuberculosis bacteria even have them in 60 locations. A difficult feat The T-A mechanism h...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... $2.50 per share, the closing price of PharmAthene's common stock on the NYSE Amex on July 24, 2009. The Warrants will be exercisable for a period of five years beginning six months after the closing of the private placement. The Company did not engage a placement agent in connection with this transactio...

Micromet Announces Pricing of Public Offering of Common Stock

...onal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of ...

Caliper Life Sciences Reports Second Quarter 2009 Results

... its first quarter results in a conference call to be held today, July 30, 2009 at 9:00 a.m. EDT. To participate in the call, please dial 888.713.4209 five to ten minutes prior to the call and use the participant passcode 64195782. International callers can access the call by dialing 617.213.4863 and ente...

U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International

...p is the only full-output pump designed to be implanted in the chest. HeartWare has completed an international clinical trial for the device involving five investigational centers in Europe and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for a bridge...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

... experiencing stable disease (SD) for more than 16 weeks, including five patients who had SD for more than 24 weeks. Patient enrolment was c...aryngeal) had partial responses (PRs) and/or clinical responses and five patients had SD for 4-8 cycles, for a total disease control rate (C...

Micromet Announces Public Offering of Common Stock

...onal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of ...

Sunesis Reports Financial Results for the Second Quarter 2009

...er as a continuous infusion of 400 mg/m2 daily for five days (CIV Schedule) or as a two hour IV bolus of 1 g/m2 daily for five days (Bolus Schedule). Across both the CIV and Bol...eated with a voreloxin dose of 80 mg/m2 or higher. five of 14 of these patients achieved a CR or CRp for a...